NRx Pharmaceuticals Seeks FDA Priority Voucher for Accelerated Review of NRX-100

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) has taken a significant step towards accelerating the review process for its NRX-100, a preservative-free intravenous ketamine formulation, by applying for the FDA Commissioner’s National Priority Voucher (CNPV) program. This move underscores the company's commitment to addressing critical U.S. health needs, particularly in the areas of suicidal depression and PTSD. The FDA's CNPV program, announced by Commissioner Marty Makary on June 17, 2025, aims to prioritize treatments that align with the nation's most pressing health challenges.

The company has already submitted the chemistry, manufacturing, and controls (CMC) portion of its application and has received feedback from the FDA, positioning NRx Pharmaceuticals for a potential accelerated review of its full New Drug Application (NDA) by late 2025. A successful application could significantly reduce the review timeline from the standard 10–12 months to just 1–2 months, marking a pivotal advancement in the treatment of severe mental health conditions.

In parallel, NRx Pharmaceuticals is pursuing a citizen petition to withdraw preservative-containing ketamine products from the market and has filed a patent for its innovative preservative-free manufacturing process. These efforts reflect the company's ambition to lead in a ketamine market projected to grow up to $5 billion annually by 2033. The potential approval and subsequent market entry of NRX-100 could offer a much-needed treatment option for patients suffering from suicidal depression and PTSD, conditions that have long demanded more effective therapeutic solutions.